Export 90 results:
Author Title [ Type(Asc)] Year
Filters: Author is Cruz, F.  [Clear All Filters]
Journal Article
Coelho, A., Oliveira, R., Cruz, F., & Cruz, C. D. (2016). Impairment of sensory afferents by intrathecal administration of botulinum toxin A improves neurogenic detrusor overactivity in chronic spinal cord injured rats. Experimental Neurology, 285, 159 - 166.
Da Silva, C. M., & Cruz, F. (2009). Has botulinum toxin therapy come of age: What do we know, what do we need to know, and should we use it?. Current Opinion in Urology, 19(4), 347 - 352.
Charrua, A., Cruz, C. D., Narayanan, S., Gharat, L., et al. (2009). GRC-6211, a New Oral Specific TRPV1 Antagonist, Decreases Bladder Overactivity and Noxious Bladder Input in Cystitis Animal Models. Journal of Urology, 181(1), 379 - 386.
Charrua, A., Reguenga, C., Cordeiro, J. M., Correiade-Sá, P., et al. (2009). Functional Transient Receptor Potential Vanilloid 1 is Expressed in Human Urothelial Cells. Journal of Urology, 182(6), 2944 - 2950.
Dinis, S., De Oliveira, J. T., Pinto, R., Cruz, F., et al. (2015). From bladder to systemic syndrome: Concept and treatment evolution of interstitial cystitis. International Journal of Women's Health, 7, 735 - 744.
Oliveira, R., Coelho, A., Charrua, A., Avelino, A., & Cruz, F. (2017). Expression of cleaved SNAP-25 after bladder wall injection of onabotulinumtoxina or abobotulinumtoxina: A comparative study in the mice. Neurourology and Urodynamics, 36(1), 86 - 90.
Gorgal, T., Charrua, A., Silva, J. F., Avelino, A., et al. (2012). Expression of apoptosis-regulating genes in the rat prostate following botulinum toxin type a injection. BMC Urology, 12.
Oliveira, R., Botelho, F., Silva, P., Resende, A., et al. (2011). Exploratory study assessing efficacy and complications of TVT-O, TVT-Secur, and Mini-Arc: Results at 12-month follow-up. European Urology, 59(6), 940 - 944.
Antunes-Lopes, T., C. da Silva, M., & Cruz, F. (2016). Evaluation of the Donor After Brain Death and Technique for Organ Procurement. European Urology, Supplements, 15(9), 390 - 396.
Cruz, C. D., & Cruz, F. (2007). The ERK 1 and 2 pathway in the nervous system: From basic aspects to possible clinical applications in pain and visceral dysfunction. Current Neuropharmacology, 5(4), 244 - 252.
Tomada, N., Tomada, I., Botelho, F., Pacheco-Figueiredo, L., et al. (2013). Endothelial function in patients with metabolic syndrome and erectile dysfunction: A question of Angiopoietin imbalance?. Andrology, 1(4), 541 - 548.
Kennelly, M., Dmochowski, R., Schulte-Baukloh, H., Ethans, K., et al. (2017). Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study. Neurourology and Urodynamics, 36(2), 368 - 375.
Martins-Silva, C., & Cruz, F. (2016). Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: Update of the Pivotal Randomised, Double-blind, Placebo-controlled Trials. European Urology Focus, 2(3), 329 - 331.
Cruz, F., Herschorn, S., Aliotta, P., Brin, M., et al. (2011). Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: A randomised, double-blind, placebo-controlled trial. European Urology, 60(4), 742 - 750.
Montorsi, F., Gandaglia, G., Chapple, C., Cruz, F., et al. (2016). Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study). International Journal of Urology, 23(7), 572 - 579.
De Carvalho, T. G. R., Pinto, R., Cruz, F., & Silva, J. (2016). Effect of onabotulinum toxin type a intraprostatic injection on the outcome of benign prostatic hyperplasia patients refractory to medical therapy: A 2-year follow-up study. Archivos Espanoles de Urologia, 69(10), 719 - 726.
Coelho, A., Dinis, P., Pinto, R., Gorgal, T., et al. (2010). Distribution of the High-Affinity Binding Site and Intracellular Target of Botulinum Toxin Type A in the Human Bladder. European Urology, 57(5), 884 - 890.
Dinis, P., Charrua, A., Avelino, A., Nagy, I., et al. (2005). The distribution of sensory fibers immunoreactive for the TRPV1 (capsaicin) receptor in the human prostate. European Urology, 48(1), 162 - 167.
Charrua, A., Reguenga, C., Paule, C. C., Nagy, I., et al. (2008). Cystitis is associated with TRPVIb-downregulation in rat dorsal root ganglia. NeuroReport, 19(15), 1469 - 1472.
Silva, J., Silva, C. M., & Cruz, F. (2014). Current medical treatment of lower urinary tract symptoms/BPH: Do we have a standard?. Current Opinion in Urology, 24(1), 21 - 28.
Chapple, C. R., Cruz, F., Deffieux, X., Milani, A. L., et al. (2017). Consensus Statement of the European Urology Association and the European Urogynaecological Association on the Use of Implanted Materials for Treating Pelvic Organ Prolapse and Stress Urinary Incontinence. European Urology, 72(3), 424 - 431.
Charrua, A., Cruz, C. D., Jansen, D., Rozenberg, B., et al. (2015). Co-administration of transient receptor potential vanilloid 4 (TRPV4) and TRPV1 antagonists potentiate the effect of each drug in a rat model of cystitis. BJU International, 115(3), 452 - 460.
Tomada, N., Tomada, I., Cruz, F., Vendeira, P., & Neves, D. (2010). Characterization of VEGF and angiopoietins expression in human corpus cavernosum during aging. Journal of Sexual Medicine, 7(4 PART 1), 1410 - 1418.
Charrua, A., Pinto, R., Taylor, A., Canelas, A., et al. (2015). Can the adrenergic system be implicated in the pathophysiology of bladder pain syndrome/interstitial cystitis? A clinical and experimental study. Neurourology and Urodynamics, 34(5), 489 - 496.
Frias, B., Allen, S., Dawbarn, D., Charrua, A., et al. (2013). Brain-derived neurotrophic factor, acting at the spinal cord level, participates in bladder hyperactivity and referred pain during chronic bladder inflammation. Neuroscience, 234, 88 - 102.

Pages


Home | Site Map | Contacts | Credits | Privacy & Cookies | Intranet | Social Networks |


rua alfredo allen, 208, 4200-135 porto - portugal | tel +351 220 408 800 | email: info@ibmc.up.pt | © copyright 2010 ibmc